<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>SHH:600276 on 无关紧要的宇宙</title><link>https://316140221.github.io/Hugo/zh/tags/shh600276/</link><description>Recent content in SHH:600276 on 无关紧要的宇宙</description><generator>Hugo</generator><language>zh-CN</language><lastBuildDate>Mon, 28 Jul 2025 02:54:34 +0800</lastBuildDate><atom:link href="https://316140221.github.io/Hugo/zh/tags/shh600276/index.xml" rel="self" type="application/rss+xml"/><item><title>Hengrui Shares Jump on GSK Deal Worth Up To $12 Billion</title><link>https://316140221.github.io/Hugo/zh/en/finance/2025-07-28-hengrui-shares-jump-on-gsk-deal-worth-up-to-12-bil/</link><pubDate>Mon, 28 Jul 2025 02:54:34 +0800</pubDate><guid>https://316140221.github.io/Hugo/zh/en/finance/2025-07-28-hengrui-shares-jump-on-gsk-deal-worth-up-to-12-bil/</guid><description>Jiangsu Hengrui Pharmaceuticals Co. shares rallied to their highest levels in four years after GSK Plc agreed to pay $500 million upfront for the company’s potential chronic lung disease treatment.</description></item><item><title>Hengrui Shares Jump on GSK Deal Worth Up To $12 Billion</title><link>https://316140221.github.io/Hugo/zh/zh/finance/2025-07-28-hengrui-shares-jump-on-gsk-deal-worth-up-to-12-bil/</link><pubDate>Mon, 28 Jul 2025 02:54:34 +0800</pubDate><guid>https://316140221.github.io/Hugo/zh/zh/finance/2025-07-28-hengrui-shares-jump-on-gsk-deal-worth-up-to-12-bil/</guid><description>Jiangsu Hengrui Pharmaceuticals Co. shares rallied to their highest levels in four years after GSK Plc agreed to pay $500 million upfront for the company’s potential chronic lung disease treatment.</description></item><item><title>Hengrui’s Obesity Drug Rivals Zepbound in Late-Stage China Trial</title><link>https://316140221.github.io/Hugo/zh/en/finance/2025-07-16-hengruis-obesity-drug-rivals-zepbound-in-late-stag/</link><pubDate>Wed, 16 Jul 2025 03:00:44 +0800</pubDate><guid>https://316140221.github.io/Hugo/zh/en/finance/2025-07-16-hengruis-obesity-drug-rivals-zepbound-in-late-stag/</guid><description>Jiangsu Hengrui Pharmaceuticals Co. and its US partner said their obesity drug candidate succeeded in a late-stage China study, a key step toward securing approval as domestic biotech firms increasing</description></item><item><title>Hengrui’s Obesity Drug Rivals Zepbound in Late-Stage China Trial</title><link>https://316140221.github.io/Hugo/zh/zh/finance/2025-07-16-hengruis-obesity-drug-rivals-zepbound-in-late-stag/</link><pubDate>Wed, 16 Jul 2025 03:00:44 +0800</pubDate><guid>https://316140221.github.io/Hugo/zh/zh/finance/2025-07-16-hengruis-obesity-drug-rivals-zepbound-in-late-stag/</guid><description>Jiangsu Hengrui Pharmaceuticals Co. and its US partner said their obesity drug candidate succeeded in a late-stage China study, a key step toward securing approval as domestic biotech firms increasing</description></item></channel></rss>